Beren Therapeutics' Adrabetadex Shows 10-Year Neurological Preservation in Infantile-Onset NPC
Event summary
- Beren Therapeutics presented new data showing adrabetadex preserved neurological function for over 10 years in children with infantile-onset NPC.
- Case study of two sisters demonstrated benefits of early treatment, with one sister starting treatment 10 months after symptom onset and the other starting 4 years after.
- Additional data showed improved survival and slower disease progression with adrabetadex treatment.
- FDA assigned a PDUFA target action date of November 17, 2026, for adrabetadex's NDA.
The big picture
Beren Therapeutics' long-term data on adrabetadex represents a significant milestone in the treatment of infantile-onset NPC, a rare and devastating neurodegenerative disease. The preservation of neurological function for over a decade highlights the potential of cyclodextrin-based therapeutics to address the underlying cause of NPC. The strategic focus on early diagnosis and treatment initiation could set a new standard for managing this condition, with implications for other rare diseases characterized by defective cholesterol trafficking.
What we're watching
- Regulatory Approval
- Whether the FDA will approve adrabetadex by the November 17, 2026 PDUFA date, given the long-term data presented.
- Treatment Paradigm
- How adrabetadex will be integrated with other NPC treatments like arimoclomol and N-acetyl-L-leucine in clinical practice.
- Market Potential
- The pace at which Beren Therapeutics can expand access to adrabetadex for other forms of NPC beyond infantile-onset.
Related topics
